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Background/Objectives: Appropriate initial treatment choices for methicillin 
resistant Staphylococcus aureus (MRSA) infections are very critical. Th e aim of 
this study was to compare the ability of Ceft obiprole, Daptomycin, Linezolid, 
Telavancin, Tigecycline, and Vancomycin to achieve their requisite pharmacokinetic/
pharmacodynamic (PK/PD) target against clinical MRSA isolates.
Methods: Monte Carlo Simulations were performed to simulate the PK/PD 
indices of the investigated antimicrobials. Population Pharmacokinetic data and 
Pharmacodynamic indices were integrated into Monte Carlo Simulation routine 
with 10,000 iterations. Probability of target attainment (PTA) was estimated at MIC 
values ranging from 0.03-32 μg/ml to defi ne the PK/PD susceptibility breakpoints. 
Cumulative fraction of response (CFR) was computed using MIC data from the 
Canadian National Ward (CAN-Ward) study collected in 2007, 2008 and 2009.
Results: Analysis of the simulation results suggested the breakpoints of 8μg/ml for 
Ceft obiprole, 0.12 μg/ml for Daptomycin and Tigecycline, 0.5 μg/ml for Telavancin 
and 1 μg/ml for Linezolid and Vancomycin. Th e estimated CFR were 100, 66.5, 84, 
89.1, 98.2, 60, 97.5 % for Ceft obiprole, Daptomycin (4mg/kg/day), Daptomycin (6mg/
kg/day), Linezolid, Telavancin, Tigecycline, Vancomycin (2gm/day) and Vancomycin 
(3gm/day), respectively. 
Conclusions: Ceft obiprole and Telavancin have the highest probability of 
achieving favorable outcome against MRSA infections. Th e susceptibility results 
suggested a further reduction of the vancomycin breakpoint to 1 μg/ml.
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